The brain drug developer is continuing a trial despite a recommendation it be stopped for futility. Elsewhere, Eli Lilly ...

The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...

The meeting, which helps the FDA give guidance to vaccine makers on which flu strains to target, is the second to be ...

Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited “changing priorities.” ...

Woven Health Collective elevates clients’ science, engages the right stakeholders, and magnifies success with a harmonized and highly specialized approach across key areas. All services are backed by ...

While announcing billions of dollars in new U.S. investments, company chief David Ricks called for an extension of 2017 tax ...

The British drugmaker claimed success in a first-line breast cancer study. Elsewhere, Rezdiffra sales continued to grow and a ...

CiteAb, a Sci-Tech company specialising in data collection, announces the launch of CiteAb Unlimited for pharmaceutical and biotechnology companies. This service provides private access to a database ...

The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry ...

If you have concerns about your use of Depo-Provera, we would like to hear from you. Please complete the contact form on this page, send us an email at [email protected], or give us a call at (202) ...

The funding comes as Eikon, run by former Merck research chief Roger Perlmutter, has started a Phase 3 trial testing one of ...